Truist notes that new data for BioNTech’s (BNTX) BNT327 in Small Cell Lung Cancer presented at World Lung today was very reassuring on two major counts, namely it confirmed that the treatment effect seen in China was replicated in a global study, and BioNTech was able to transition the dose from Q2W to an equivalent Q3W for the global development effort of BNT327. Truist points out that BioNTech and partner Bristol-Myers Squibb (BMY) are leading the race among the PD-(L)1 x VEGF bispecifics in SCLC, with a Phase 3 study underway. The firm projects a launch in 2028, and sees this as a potential $1.4B revenue opportunity for the drug. BofA has a Buy rating on BioNTech with a price target of $155 on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech, Bristol Myers present interim data from a Phase 2 pumitamig trial
- BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy
- BioNTech’s Oncology Success and Robust Pipeline Drive Buy Rating
- Pfizer, BioNTech announce results from Phase 3 trial of LP.8.1-adapted COMIRNATY
- BioNTech building integrated oncology pipeline, says Clear Street